氟氧头孢用于新生儿:扩展产ESBL肠杆菌目所致新生儿脓毒症的治疗选择
该系统综述汇总氟氧头孢在新生儿中的临床与药代动力学数据,构建首个新生儿群体药代动力学模型并进行蒙特卡罗模拟。313例新生儿临床数据显示临床成功率89.71%、微生物学成功率82.8%,副作用少。模型纳入体重和日龄,预测0-7天、7-14天和14-28天新生儿分别适用20 mg/kg q12h、20 mg/kg q6-8h和40 mg/kg q6-8h静脉方案。
要点
- 临床成功率89.71%,微生物学成功率82.8%,副作用少。
- 首个新生儿氟氧头孢群体药代动力学模型,纳入体重和日龄。
- 预测0-7天、7-14天、14-28天分别适用20 mg/kg q12h、20 mg/kg q6-8h、40 mg/kg q6-8h静脉方案。
核心结论
- 据作者所知,这是首个已发表的新生儿氟氧头孢群体药代动力学模型。
- 鉴于高治疗成功率、低毒性率和专利到期状态,该药在产ESBL流行的中低收入国家新生儿脓毒症治疗中具有应用潜力。
研究设计与样本
- 系统文献检索获取新生儿氟氧头孢所有可用的临床或药代动力学数据。
- 利用药代动力学数据构建群体药代动力学模型,逐步将协变量纳入最终模型。
- 使用最终模型进行蒙特卡罗模拟,模拟不同氟氧头孢方案的药物暴露以计算PTA。
主要发现
- 提取了313例新生儿的个体水平临床数据和146例新生儿的药代动力学数据,另提取了199例新生儿的人群临床数据。
- 临床成功率和微生物学成功率分别为89.71%和82.8%,副作用极少。
- 最终群体药代动力学模型纳入体重和日龄作为协变量。
- PTA分析预测,静脉方案20 mg/kg q12h、20 mg/kg q6-8h和40 mg/kg q6-8h分别适用于0-7日龄、7-14日龄和14-28日龄新生儿。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neonatal sepsis is a serious and frequently lethal infection, often complicated by antimicrobial resistance (including ESBLs) in low- and middle-income countries (LMICs). Flomoxef is an off-patent oxacephem β-lactam with stability against non-AmpC ESBLs, with potential for utility in these settings. To date, there has been no published flomoxef neonatal population pharmacokinetic (PopPK) model. OBJECTIVES: To summarize the clinical data available for flomoxef, build a neonatal PopPK model and assess the adequacy of different neonatal flomoxef regimens. METHODS: A systematic literature search returned all available clinical or pharmacokinetic data of flomoxef use in neonates. Pharmacokinetic data were used to construct a PopPK model, with progressive incorporation of covariates into the final model. Monte Carlo simulations were performed using this final model to simulate drug exposures of different flomoxef regimens to calculate PTAs. RESULTS: Individual-level clinical and pharmacokinetic data were extracted for 313 and 146 neonates, respectively, with population clinical data extracted for a further 199 neonates. Clinical and microbiological success rates were 89.71% and 82.8%, respectively, with minimal side effects. The final PopPK model incorporated body weight and postnatal age as covariates. PTA analyses predicted that IV regimens of 20 mg/kg q12h, 20 mg/kg q6-8h and 40 mg/kg q6-8h are adequate for neonates aged 0-7, 7-14 and 14-28 days, respectively. CONCLUSIONS: To the best of our knowledge, this is the first published neonatal PopPK model for flomoxef. Given the high treatment success rates, low toxicity rates and off-patent status, this drug has potential for use in the treatment of neonatal sepsis in ESBL-prevalent LMIC settings.
引用
- Darlow CA, Hope W. Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales. J Antimicrob Chemother. 2022. PMID: 34969066. doi:10.1093/jac/dkab468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。